The cash flow estimate points to the retatrutide phase 3 win and a deeper pipeline as reasons Lilly's value could sit above today's share price.
Recap by typeshit. Full story at Yahoo Finance.
GEN ranks the best-selling drugs by 2025 sales, and Lilly's weight loss shot outpaced names like Merck's Keytruda on growth.
A Dongguk University family medicine professor calls gallbladder risk the real concern and says some Koreans fly to Japan, where the drugs reportedly cost about a third.
Ricks describes working with the Trump administration to lower obesity drug costs for older Americans, on the day Lilly posted third-quarter earnings.
Walmart and Bank of America are expanding coverage, while 10% of surveyed employers say they may drop it in 2027. Workers explain what coverage means for their budgets.
CNA Lifestyle asked doctors how the oral and injectable forms of Wegovy differ and what risks people should weigh before trying either.
Famtimes says habits like diet and exercise matter for keeping weight off once GLP-1 treatment ends.
Loading…